| HOME >> MEDICINE >> TECHNOLOGY |
219Litigation settlement (operating expense)
(2,439)--Subtotal pretax adjustments
(739)--Income tax effect of non-GAAP adjustments
326Taxes on repatriated foreign earnings
574ASC 718 share-based compensation adjustment Gross profit
293363360Operating expenses
1,9051,7342,053Total after tax adjustments
2,359
0.072,097
0.062,413
0.07Non-GAAP$
3,635
$
.11$
4,062
$
.12$
3,267
$
.10Omnicell, Inc.Reconciliation of GAAP to Non-GAAP(In thousands, except per share data, unaudited)Nine months endedSeptember 30, 2010September 30, 2009NetincomeEarningsper share-dilutedNetIncome(loss)Earnings(loss)per share-dilutedGAAP$
4,220
$
.13$
(112)
$
-Non-GAAP adjustments:Restructuring cost Gross profit
391,209Operating expenses
1,1571,315Reduction-in-force, other exit related charges Gross profit
285Operating expenses
219Litigation settlement (operating expense)
(2,439)-Subtotal pretax adjustments
(739)2,524Income tax effect of non-GAAP adjustments
326(991)Taxes on repatriated foreign earnings
574ASC 718 share-based compensation adjustment Gross profit
9771,026Operating expenses
5,4746,245Total after tax adjustments
6,612
0.198,804
0.28Non-GAAP$
,832
| SOURCE Omnicell, Inc. Copyright©2010 PR Newswire. All rights reserved |